May 2017 Newsletter

Home/Diabetes Bites/May 2017 Newsletter

BG control in Type 1 Diabetes Improves with Fast-Acting Insulin Aspart

By | 2017-05-18T18:17:19+00:00 May 18th, 2017|May 2017 Newsletter|

According to a study published online in Diabetes Care on April 11, fast-acting insulin aspart (faster aspart) improved blood glucose control in patients with Type 1 diabetes, as compared to the conventional formulation of the drug, insulin aspart (IAsp). In the United States, insulin aspart is better known as Novo Nordisk's insulin Novolog. In many other countries, it is known as NovoRapid.

My Review of Afrezza Fast Acting Inhaled Insulin

By | 2017-05-24T15:00:11+00:00 May 18th, 2017|Diabetes Bites, May 2017 Newsletter, Thinking Like A Pancreas Blog|

By avoiding the need to absorb through the fat layer below the skin, Afrezza starts working almost immediately, peaks in about 15 minutes, and in most cases, clears in about 2 hours. Now that’s rapid!